Medical polymer composition and medical adhesive containing same
A copolymer with catechol and hydrophilic (meth)acrylate monomers, combined with an alcohol solvent, addresses the limitations of existing medical adhesives by providing strong, flexible, and biocompatible bonding for biological tissues and devices, enhancing medical application efficacy and safety.
Patent Information
- Application Number
- PCT/JP2024/018197
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-18
- Filing Date
- 2024-05-16
- Publication Date
- 2024-11-21
AI Technical Summary
Current medical adhesives, such as fibrin glue and cyanoacrylate, face issues like low adhesive strength, toxicity, brittleness, and poor flexibility, especially when used in wet conditions or on soft tissues, limiting their effectiveness and safety for medical applications.
A medical polymer composition comprising a copolymer with a monomer having a catechol group and a hydrophilic (meth)acrylate monomer, combined with an alcohol-based solvent, which enhances adhesion to biological tissues in a wet state while ensuring biocompatibility and safety.
The medical polymer composition exhibits high adhesive strength and flexibility, enabling effective bonding of biological tissues and medical devices, reducing inflammation, bleeding, and preventing complications like stenosis and fistula formation, while being safe for use in living organisms.
Smart Images

Figure JP2024018197_21112024_PF_FP_ABST
Abstract
Description
Medical polymer composition and medical adhesive containing same
[0001] The present invention relates to a medical polymer composition containing a copolymer such as poly(meth)acrylate and an alcohol-based solvent, and a medical adhesive containing the same.
[0002] Medical adhesives require adhesiveness in wet conditions, so fibrin glue and cyanoacrylate adhesives are the mainstream, and there are few materials that can be used. However, fibrin glue has problems such as the need to properly mix fibrinogen and thrombin, low adhesive strength, and concerns about viral infection. Cyanoacrylate adhesives also have problems such as generating toxic formaldehyde upon hydrolysis, exhibiting brittleness in the cured product, and poor flexibility that prevents them from conforming to soft tissue. As a result, their applications are limited, and new medical adhesives are desired.
[0003] In recent years, mimicking the marine organism Mytilus galloprovincialis has attracted attention due to its high adhesive properties to wet substrates. Mytilus galloprovincialis attaches to rocks and reefs using adhesive proteins called byssus threads. It has been revealed that the catechol structure contributes to the adhesion to wet substrates. Therefore, the development of materials with this or similar structures in their skeletons is progressing.
[0004] For example, Non-Patent Document 1 shows that modifying hyaluronic acid with a catechol group improves adhesive strength compared to unmodified hyaluronic acid. Although it can adhere to an adherend in a wet state, there is a problem that the adhesive strength is insufficient.
[0005] Furthermore, Non-Patent Document 2 shows that introducing catechol groups into hydroxybutylchitosan improves adhesive strength to eight times that of chitosan. Although it can adhere to an adherend in a wet state, the adhesive strength is less than half that of Non-Patent Document 1, which is a problem of insufficient adhesive strength.
[0006] Patent Documents 1 to 4 disclose copolymers having catechol groups in the side chains of acrylic polymers.
[0007] In the examples of Patent Document 1, the copolymer is dissolved in methyl ethyl ketone, and the adhesive performance to glass, acrylic, or polycarbonate is evaluated. However, methyl ethyl ketone is a highly toxic solvent and cannot be used in living organisms. Furthermore, there is no mention of adhesive performance to substrates or biological tissues in a wet environment.
[0008] In Patent Document 2, the adhesive performance to inorganic materials and synthetic polymers is evaluated in the examples, but there is no mention of adhesive performance to substrates or biological tissues in a wet environment.
[0009] In the examples of Patent Document 3, a polymer into which boronic acid has been introduced is used, and adhesive performance to glass in water is evaluated. However, the examples do not describe the use of a catechol group, and do not mention adhesive performance to biological tissue.
[0010] Patent Document 4 discloses a bioabsorbable adhesive in which a catechol group is introduced into the side chain of an aliphatic polycarbonate. However, only the bone bonding property is evaluated, and no data on adhesive performance to soft tissues is disclosed, and thus the results are unclear.
[0011] European Polymer Journal, 2020, 134, 109763-109772ACS Biomater. Sci. Eng. 2020, 6, 3619-3629
[0012] International Publication No. 2019 / 194047 International Publication No. 2019 / 221135 International Publication No. 2021 / 020451 Japanese Patent Application Laid-Open No. 2021-142049
[0013] Under these circumstances, the present invention aims to provide a medical adhesive that has high adhesive strength to materials in a wet state.
[0014] As a result of extensive research into the present invention, the inventors have found that the above-mentioned problems can be solved by a medical polymer composition containing a copolymer containing, as constituent components, a monomer represented by the following formula (1) and a (meth)acrylate monomer having a hydrophilic group, and an alcohol-based solvent, as well as a medical adhesive containing the same, and have completed the present invention.
[0015]
[0016] The present invention includes, for example, the subject matter described in the following items: [1] A medical polymer composition comprising a copolymer (P) containing, as constituent components, a monomer (A) represented by the following formula (1) and a (meth)acrylate monomer (B) having a hydrophilic group, and an alcohol-based solvent (S). (In the formula, R 1 represents a hydrogen atom or a methyl group, L represents an amide bond, an ester bond or a direct bond, x represents 0 or an integer of 1 to 10, and y represents an integer of 1 to 5.
[0017] According to the present invention, it is possible to provide a medical polymer composition having high adhesiveness to materials in a wet state, and a medical adhesive containing the same.
[0018] The present invention will be described in detail below. However, the present invention is not limited to the embodiments described below. Furthermore, (meth)acrylate refers to methacrylate and acrylate, and (meth)acrylic refers to methacrylic and acrylic.
[0019] The medical polymer composition of the present invention comprises a copolymer (P) containing as constituent components a monomer (A) represented by the following formula (1) and a (meth)acrylate monomer (B) having a hydrophilic group, and an alcohol-based solvent (S). By including the monomer (A) as a constituent component of the copolymer (P), it is possible to impart excellent adhesiveness to wet biological tissue. Furthermore, by including the monomer (B) as a constituent component of the copolymer (P), it is possible to adjust (increase) the affinity with the alcohol-based solvent.
[0020] In formula (1), R 1represents a hydrogen atom or a methyl group, and L represents an amide bond, an ester bond, or a direct bond. x represents 0 or an integer of 1 to 10, preferably 0 or an integer of 1 to 5, and more preferably 0 or an integer of 1 to 3. y represents an integer of 1 to 5, preferably an integer of 1 to 3, more preferably 2 or 3, and even more preferably 2.
[0021] The monomer (A) is preferably a monomer represented by the following formula (1a): (In the formula, each symbol is the same as defined above.)
[0022] When L is an amide bond, the monomer (A) is preferably (meth)acrylamide. Examples thereof include N-[2-(3,4-dihydroxyphenyl)methyl](meth)acrylamide, N-[2-(3,4-dihydroxyphenyl)ethyl](meth)acrylamide, N-[2-(3,4-dihydroxyphenyl)propyl](meth)acrylamide, N-[2-(3,4-dihydroxyphenyl)butyl](meth)acrylamide, N-[2-(3,4-dihydroxyphenyl)pentyl](meth)acrylamide, and N-[2 -(3,4-dihydroxyphenyl)hexyl](meth)acrylamide, N-[2-(3,4-dihydroxyphenyl)heptyl](meth)acrylamide, N-[2-(3,4-dihydroxyphenyl)octyl](meth)acrylamide, N-[2-(3,4-dihydroxyphenyl)nonyl](meth)acrylamide, N-[2-(3,4-dihydroxyphenyl)decyl](meth)acrylamide, N-[2-(3,4,5-trihydroxyphenyl)hexyl](meth)acrylamide
[0111] N-[2-(3,4,5-trihydroxyphenyl)methyl](meth)acrylamide, N-[2-(3,4,5-trihydroxyphenyl)ethyl](meth)acrylamide, N-[2-(3,4,5-trihydroxyphenyl)propyl](meth)acrylamide, N-[2-(3,4,5-trihydroxyphenyl)butyl](meth)acrylamide, N-[2-(3,4,5-trihydroxyphenyl)pentyl](meth)acrylamide, N-[2-(3,4,5-trihydroxyphenyl)hexyl](meth)acrylamide, N-[2-(3,4,5-trihydroxyphenyl)heptyl](meth)acrylamide, N-[2-(3,4,5-trihydroxyphenyl)octyl](meth)acrylamide, N-[2-(3,4,5-trihydroxyphenyl)nonyl](meth)acrylamide, N-[2-(3,4,5-trihydroxyphenyl)decyl](meth)acrylamide, and the like.
[0023] When L is an ester bond, the monomer (A) is preferably a (meth)acrylic acid ester. Examples thereof include (meth)acrylic acid 2-(3,4-dihydroxyphenyl)methyl ester, (meth)acrylic acid 2-(3,4-dihydroxyphenyl)ethyl ester, (meth)acrylic acid 2-(3,4-dihydroxyphenyl)propyl ester, (meth)acrylic acid 2-(3,4-dihydroxyphenyl)butyl ester, (meth)acrylic acid 2-(3,4-dihydroxyphenyl)pentyl ester, (meth)acrylic acid 2-(3,4-dihydroxyphenyl)hexyl ester, (meth)acrylic acid 2-(3,4-dihydroxyphenyl)heptyl ester, (meth)acrylic acid 2-(3,4-dihydroxyphenyl)octyl ester, (meth)acrylic acid 2-(3,4-dihydroxyphenyl)nonyl ester, (meth)acrylic acid 2-(3,4-dihydroxyphenyl)decyl ester, and (meth)acrylic acid 2-(3, (meth)acrylic acid-2-(3,4,5-trihydroxyphenyl)methyl ester, (meth)acrylic acid-2-(3,4,5-trihydroxyphenyl)ethyl ester, (meth)acrylic acid-2-(3,4,5-trihydroxyphenyl)propyl ester, (meth)acrylic acid-2-(3,4,5-trihydroxyphenyl)butyl ester, (meth)acrylic acid-2-(3,4,5-trihydroxyphenyl)pentyl ester, (meth)acrylic acid-2-(3,4,5-trihydroxyphenyl)hexyl ester, (meth)acrylic acid-2-(3,4,5-trihydroxyphenyl)heptyl ester, (meth)acrylic acid-2-(3,4,5-trihydroxyphenyl)octyl ester, (meth)acrylic acid-2-(3,4,5-trihydroxyphenyl)nonyl ester, and (meth)acrylic acid-2-(3,4,5-trihydroxyphenyl)decyl ester.
[0024] When L is a direct bond, examples of the monomer (A) include 3,4-dihydroxystyrene, 3-(3,4-dihydroxyphenyl)-1-propene, 4-(3,4-dihydroxyphenyl)-1-butene, 5-(3,4-dihydroxyphenyl)-1-pentene, 6-(3,4-dihydroxyphenyl)-1-hexene, 7-(3,4-dihydroxyphenyl)-1-heptene, 8-(3,4-dihydroxyphenyl)-1-octene, 9-(3,4-dihydroxyphenyl)-1-nonene, 10-(3,4-dihydroxyphenyl)-1-propene, 11-(3,4-dihydroxyphenyl)-1-pentene, 12-(3,4-dihydroxyphenyl)-1-pentene, 13-(3,4-dihydroxyphenyl)-1-pentene, 14-(3,4-dihydroxyphenyl)-1-pentene, 15-(3,4-dihydroxyphenyl)-1-pentene, 16-(3,4-dihydroxyphenyl)-1-hexene, 17-(3,4-dihydroxyphenyl)-1-heptene, 18-(3,4-dihydroxyphenyl)-1-octene, 19-(3,4-dihydroxyphenyl)-1-nonene, 20-(3,4-dihydroxyphenyl)-1-pentene, 21-(3,4-dihydroxyphenyl)-1-pentene, 22-(3,4-dihydroxyphenyl)-1-pentene, 23-(3,4-dihydroxyphenyl)-1-pentene, 24-(3,4-dihydroxyphenyl)-1-pentene, 25-(3,4-dihydroxyphenyl)-1-pentene, 26-(3,4-dihydroxyphenyl)-1-pentene, 27-(3,4-dihydroxyphenyl)-1-pentene, 28-(3,4-dihydroxyphenyl)-1 )-1-decene, 3-(3,4-dihydroxyphenyl)-2-methyl-1-propene, 4-(3,4-dihydroxyphenyl)-2-methyl-1-butene, 5-(3,4-dihydroxyphenyl)-2-methyl-1-pentene, 6-(3,4-dihydroxyphenyl)-2-methyl-1-hexene, 7-(3,4-dihydroxyphenyl)-2-methyl-1-heptene, 8-(3,4-dihydroxyphenyl)-2-methyl-1-octene, 9-(3,4-dihydroxyphenyl)-2-methyl-1-nonene, 10-(3,4-dihydroxyphenyl)-2-methyl-1-pentene (3,4,5-trihydroxyphenyl)-2-methyl-1-decene, 3,4,5-trihydroxystyrene, 3-(3,4,5-trihydroxyphenyl)-1-propene, 4-(3,4,5-trihydroxyphenyl)-1-butene, 5-(3,4,5-trihydroxyphenyl)-1-pentene, 6-(3,4,5-trihydroxyphenyl)-1-hexene, 7-(3,4,5-trihydroxyphenyl)-1-heptene, 8-(3,4,5-trihydroxyphenyl)-1-octene, 9-(3,4,5-trihydroxyphenyl)-1-nonene, 10 -(3,4,5-trihydroxyphenyl)-1-decene, 3-(3,4,5-trihydroxyphenyl)-2-methyl-1-propene, 4-(3,4,5-trihydroxyphenyl)-2-methyl-1-butene, 5-(3,4,5-trihydroxyphenyl)-2-methyl-1-pentene, 6-(3,4,5-trihydroxyphenyl)-2-methyl-1-hexene, 7-(3,4,5-trihydroxyphenyl)-2-methyl-1-heptene, 8-(3,4,5-trihydroxyphenyl)-2-methyl-1-octene, 9-(3,4,5-trihydroxyphenyl)-2-methyl-1-nonene, 10-(3,4,5-trihydroxyphenyl)-2-methyl-1-decene, etc.
[0025] Among these, N-[2-(3,4-dihydroxyphenyl)ethyl]methacrylamide (formula (3) below) or 2-(3,4-dihydroxyphenyl)ethyl methacrylate (formula (4) below) is preferred as the monomer (A) because of its easy availability. 2-(3,4-dihydroxyphenyl)ethyl methacrylate is even more preferred. Hydroxytyrosol, the raw material for 2-(3,4-dihydroxyphenyl)ethyl methacrylate, is a substance used as a supplement raw material and can be produced by plant extraction or biosynthesis.
[0026]
[0027]
[0028] As the monomer (B), it is preferable to use at least one (meth)acrylate monomer having a hydrophilic group such as a carboxyl group, a hydroxyl group, a sulfonate ion, or an ammonium ion. Among them, it is more preferable to use at least one (meth)acrylate monomer having a hydroxyl group, since this allows adjustment of the solubility in water to prevent dissolution of the polymer by water in the living body.
[0029] Examples of (meth)acrylate monomers having a hydroxy group include 2-hydroxyethyl (meth)acrylate, 2-hydroxypropyl (meth)acrylate, 4-hydroxybutyl (meth)acrylate, 6-hydroxyhexyl (meth)acrylate, 8-hydroxyoctyl (meth)acrylate, 10-hydroxydecyl (meth)acrylate, 12-hydroxylauryl (meth)acrylate, (4-hydroxymethylcyclohexyl)methyl acrylate, and N-methylol (meth)acrylamide. Of these, 2-hydroxyethyl (meth)acrylate and 2-hydroxypropyl (meth)acrylate are preferred because they allow for easy adjustment of the solubility in ethanol and water.
[0030] The monomer (B) is preferably a (meth)acrylate monomer having a hydroxy group, represented by the following formula (2). (In the formula, R 2 represents a hydrogen atom or a methyl group, and z represents an integer of 1 to 10.
[0031] In formula (2), R 2 represents a hydrogen atom or a methyl group; z represents an integer of 1 to 10, preferably an integer of 1 to 5, and more preferably an integer of 1 to 3.
[0032] From the viewpoint of improving adhesiveness to wet tissues, the constituent ratio of the monomer (A) is preferably 0.01 mol% or more, more preferably 0.1 mol% or more, and even more preferably 1 mol% or more, based on the total copolymer (P). Furthermore, from the viewpoint of solubility in alcohol-based solvents, it is preferably 30 mol% or less, more preferably 20 mol% or less, even more preferably 15 mol% or less, and particularly preferably 10 mol% or less. If the constituent ratio of the monomer (A) is too low, sufficient adhesive performance tends to be insufficient for wet materials (especially biological tissues). Furthermore, if the constituent ratio of the monomer (A) is too high, the solubility in alcohol-based solvents decreases, forcing the solids concentration in the adhesive composition to be lowered, making it difficult to demonstrate adhesive performance.
[0033] From the viewpoint of improving adhesiveness, the weight-average molecular weight of the copolymer (P) is preferably 50,000 or more, more preferably 100,000 or more, and even more preferably 150,000 or more. Furthermore, from the viewpoint of solubility in alcohol-based solvents, it is preferably 500,000 or less, more preferably 400,000 or less, and even more preferably 300,000 or less. If the weight-average molecular weight is too small, the mechanical strength of the copolymer (P) decreases, and the adhesive strength and tissue bonding ability decrease, tending to make it difficult to obtain sufficient adhesive performance. Furthermore, if the weight-average molecular weight is too large, the solubility in alcohol-based solvents decreases, forcing the solids concentration in the adhesive composition to be lowered, making it difficult to exhibit adhesive performance.
[0034] The polymerization method for the copolymer (P) is not particularly limited, and various known methods can be used for polymerization. For example, the copolymer (P) can be polymerized by dissolving the monomer (A), the monomer (B), and other monomers in an organic solvent, adding a polymerization initiator, and then heating or irradiating the monomer with light.
[0035] Examples of organic solvents that can be used in the polymerization of the copolymer (P) include N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), N,N-dimethylacetamide (DMAc), N-methylpyrrolidone (NMP), 1,4-dioxane, toluene, xylene, hexane, heptane, ethyl acetate, etc. Since it is used for medical purposes, dimethyl sulfoxide, which has a proven track record of use in pharmaceuticals, is preferred.
[0036] As the polymerization initiator, it is preferable to use, for example, an azo compound such as 2,2'-azobisbutyronitrile (AIBN) or a peroxide such as benzoyl peroxide (BPO).
[0037] The alcohol-based solvent (S) is preferably ethanol, isopropanol, or a mixture thereof from the viewpoint of improving adhesiveness, and is more preferably ethanol from the viewpoint of biocompatibility, volatility, and polymer solubility.
[0038] The solids concentration of the medical polymer composition of the present invention, i.e., the concentration of the copolymer (P), is preferably 5% by mass or more, and even more preferably 10% by mass or more, from the viewpoint of curing time. It may also be 20% by mass or more, or even 25% by mass or more. From the viewpoint of solubility in alcohol-based solvents, it is preferably 40% by mass or less, and more preferably 35% by mass or less. If the solids concentration is too low, curing takes a long time, and it tends to be difficult to exhibit adhesive performance. If the solids concentration is too high, it tends to be difficult to exhibit adhesive performance, as it tends to be difficult to exhibit solubility in alcohol-based solvents.
[0039] The medical polymer composition of the present invention exhibits excellent adhesion to wet materials (especially biological tissues), and can therefore be used as a medical adhesive for coating the surface of biological tissue, joining biological tissues together, and joining biological tissues to medical devices. Specifically, the medical polymer composition of the present invention can be used as an adhesive for at least one application selected from the group consisting of preventing inflammation, bleeding, and stenosis inside the digestive tract due to resection, preventing colonic anastomotic failure, preventing pancreatic fistula, preventing bleeding after dialysis shunt formation, preventing the enlargement of varicose veins in the lower limbs, and preventing vascular stenosis. Examples of biological tissues that can be used as adherends include the skin, organs, and blood vessels of fish, amphibians, reptiles, birds, humans, and non-human mammals (e.g., cows, sheep, horses, pigs, mice, rats, guinea pigs, hamsters, dogs, cats, rabbits, etc.). Examples of medical devices that can serve as adherends include catheters, sutures, endoscopes, syringes, injectors, pumps, filters, artificial joints, artificial blood vessels, and artificial organs.
[0040] The method of use of the medical adhesive of the present invention is not particularly limited, but it may be applied to the biological tissue to be adhered and dried to form a coating. Alternatively, it may be applied to the site of anastomosis using sutures or the like and dried. Furthermore, it may be injected into a vein and allowed to harden within the blood vessel. It can be used appropriately depending on the application.
[0041] The thickness of the adhesive layer is not particularly limited and may be determined appropriately depending on the application.
[0042] The present invention will be explained in more detail below with reference to examples. The present invention is not limited to the following examples, and modifications can of course be made within the scope of the above and below-described aims, and all such modifications are included within the technical scope of the present invention. Analysis or evaluation in the examples and comparative examples was carried out as follows.
[0043] (Method for measuring weight-average molecular weight) Measurement was carried out using a gel permeation chromatograph (TOSOH HLC-8420GPC). A sample solution was prepared to a concentration of 0.2% by mass and filtered through a membrane filter before use. Two TSKgel SuperAWM-H (Tosoh Corporation) columns were used, and the injection volume was 10 μl, the mobile phase was DMAc supplemented with 30 mM LiBr, the flow rate was 0.3 ml / min, and the temperature was 40°C. Detection was carried out using a refractive index detector (RI), and the molecular weight was calculated in terms of standard polystyrene.
[0044] Synthesis Example 1 (Synthesis of Monomer) Under a nitrogen atmosphere, 7.75 g (50 mmol) of hydroxytyrosol (HT), 0.985 g (5 mmol) of p-toluenesulfonic acid monohydrate, and 55 ml (500 mmol) of methyl methacrylate (MMA) were placed in a 150 ml recovery flask and heated with stirring at 100° C. The reaction was analyzed by thin layer chromatography (developing solvent: 100% ethyl acetate) and 1 The reaction mixture was monitored by H-NMR. After 6 hours, the reaction solution was returned to room temperature and the reaction was stopped using a saturated aqueous solution of sodium bicarbonate. The reaction solution was extracted three times with ethyl acetate and washed with a saturated aqueous solution of sodium chloride. The obtained organic layer was dried over magnesium sulfate, and the solvent was then distilled off. The obtained crude product was dissolved in methanol and washed three times with hexane, and the solvent was then distilled off. The product was then purified by silica gel column chromatography (developing solvent: ethyl acetate / hexane = 30 / 70 (volume ratio)), and 9.9 g of methacrylic acid-2-(3,4-dihydroxyphenyl)ethyl ester (MMA-HT) was obtained (yield 89%). The compound was identified by 1 H-NMR was performed.
[0045] Example 1 Synthesis of Copolymer and Preparation of Medical Polymer Composition Under a nitrogen atmosphere, 0.81 g (3.6 mmol) of MMA-HT, 3.18 g (24.4 mmol) of 2-hydroxyethyl methacrylate (HEMA), 11.95 g of DMF, and 0.05 g (0.3 mmol) of AIBN were added to a 30 ml recovery flask, and the mixture was reacted at 65°C for 28 hours to prepare a copolymer. 1The ratio of hydroxyethyl groups to 3,4-dihydroxyphenyl groups determined by H-NMR was 12 / 88 (molar ratio). The weight average molecular weight (Mw) was 329,300. The copolymer was mixed with ethanol so that the solids concentration was 32% by mass, thereby preparing a polymer composition.
[0046] Examples 2 to 5 Copolymers of Examples 2 to 5 were synthesized by changing the charging ratio of MMA-HT and HEMA in the same manner as in Example 1. The composition ratio and Mw of each copolymer are shown in Table 1. Furthermore, each copolymer was mixed with ethanol so that the solid content concentration was 32 mass % to prepare a polymer composition.
[0047] Example 6 The copolymer obtained in Example 1 and isopropanol were mixed so that the solid content concentration was 32% by mass to prepare a polymer composition.
[0048] Comparative Example 1: Under a nitrogen atmosphere, 1.96 g (15.0 mmol) of HEMA, 7.81 g of DMF, and 0.05 g (0.3 mmol) of AIBN were added to a 30 ml recovery flask and reacted at 60° C. for 13 hours to produce a polymer. The weight average molecular weight (Mw) was 117,200. The polymer and ethanol were mixed to give a solids concentration of 32% by mass to produce a polymer composition.
[0049] Comparative Example 2: Under a nitrogen atmosphere, 0.44 g (2.0 mmol) of MMA-HT, 1.80 g (18.0 mmol) of MMA, 8.54 g of DMF, and 0.03 g (0.2 mmol) of AIBN were added to a 30 ml recovery flask and reacted at 65°C for 13 hours to produce a polymer. The weight average molecular weight (Mw) was 152,000. The copolymer and ethanol were mixed so that the solid content concentration was 32% by mass, to produce a polymer composition.
[0050] Comparative Example 3 The copolymer obtained in Example 1 and DMSO were mixed so that the solid content concentration was 32% by mass to prepare a polymer composition.
[0051] (Tensile Adhesion Test) The test was performed according to the following procedure. The substrate was a PET film (Toyobo Co., Ltd., Model No. A4381) cut to a width of 15 mm and a length of 60 mm, with the backside of pig skin cut into 15 mm squares attached to the edge using Aron Alpha (Toa Gosei Co., Ltd., Model No. 201). Two samples were prepared by applying a polymer composition (15 mg of polymer) to the surface of the pig skin, bonding the two together, securing them with clips, and drying them at 37°C for 1 hour to prepare test specimens. A tensile adhesion test was performed using a tensile tester (A&D Co., Ltd., RTG-1310) under conditions of a temperature of 23°C, a relative humidity of 27%, a chuck distance of 35 mm, and a tensile speed of 10 mm / min. The results obtained using each polymer composition are shown in Table 1.
[0052]
[0053] The medical polymer composition of the present invention exhibits excellent adhesive properties to wet biological tissues, and is therefore expected to make a significant contribution to various medical applications as a medical adhesive.
[0054] The present invention provides the following aspects: [1] A medical polymer composition comprising a copolymer (P) containing, as constituent components, a monomer (A) represented by the following formula (1) and a (meth)acrylate monomer (B) having a hydrophilic group, and an alcohol-based solvent (S). (In the formula, R 1represents a hydrogen atom or a methyl group, L represents an amide bond, an ester bond, or a direct bond, x represents 0 or an integer of 1 to 10, and y represents an integer of 1 to 5.) [2] The medical polymer composition according to [1], wherein the constituent ratio of the monomer (A) is 0.01 to 30 mol% relative to the entire copolymer (P). [3] The medical polymer composition according to [1] or [2], wherein the weight-average molecular weight of the copolymer (P) is 50,000 or more and 500,000 or less. [4] The medical polymer composition according to any of [1] to [3], wherein the alcohol-based solvent (S) is ethanol, isopropanol, or a mixed solvent thereof. [5] The medical polymer composition according to any of [1] to [4], wherein the solid content concentration is 1 to 40 mass%. [6] The medical polymer composition according to any of [1] to [5], wherein the monomer (A) is represented by the following formula (1a): (In the formula, R 1 represents a hydrogen atom or methyl, L represents an amide bond, an ester bond or a direct bond, and x represents 0 or an integer of 1 to 10. [7] The medical polymer composition according to any one of [1] to [6], wherein the (meth)acrylate monomer (B) is represented by the following formula (2): (In the formula, R 2 represents a hydrogen atom or a methyl group, and z represents an integer of 1 to 10.) [8] A medical adhesive comprising the medical polymer composition according to any one of [1] to [7]. [9] The medical adhesive according to [8], which is used for at least one application selected from the group consisting of coating the surface of biological tissue, joining biological tissues together, and joining biological tissue to a medical device.
[10] The medical adhesive according to [8] or [9], characterized in that it is an adhesive that can be used to prevent inflammation, bleeding, and stenosis inside the digestive tract, prevent colonic anastomotic failure, prevent pancreatic fistula, prevent bleeding from dialysis shunts, and prevent varicose veins and vascular stenosis in the lower limbs.
[11] Use of a composition as a medical adhesive, which comprises a copolymer (P) containing, as constituent components, a monomer (A) represented by the following formula (1) and a (meth)acrylate monomer (B) having a hydrophilic group, and an alcohol-based solvent (S): (In the formula, R 1represents a hydrogen atom or a methyl group, L represents an amide bond, an ester bond or a direct bond, x represents 0 or an integer of 1 to 10, and y represents an integer of 1 to 5.
Claims
1. A medical polymer composition comprising a copolymer (P) containing as components a monomer (A) represented by the following formula (1) and a (meth)acrylate monomer (B) having a hydrophilic group, and an alcohol-based solvent (S). (In the formula, R 1 represents a hydrogen atom or a methyl group, L represents an amide bond, an ester bond or a direct bond, x represents 0 or an integer of 1 to 10, and y represents an integer of 1 to 5.
2. The medical polymer composition according to claim 1, wherein the constituent ratio of said monomer (A) is 0.01 to 30 mol % based on the entire copolymer (P).
3. The medical polymer composition according to claim 1, wherein the weight average molecular weight of the copolymer (P) is 50,000 or more and 500,000 or less.
4. The medical polymer composition according to claim 1, wherein the alcohol-based solvent (S) is ethanol, isopropanol, or a mixture thereof.
5. The medical polymer composition according to claim 1, having a solids concentration of 1 to 40% by mass.
6. The medical polymer composition according to claim 1, wherein the monomer (A) is represented by the following formula (1a): (In the formula, R 1 represents a hydrogen atom or methyl, L represents an amide bond, an ester bond or a direct bond, and x represents 0 or an integer of 1 to 10.
7. The medical polymer composition according to claim 1, wherein the (meth)acrylate monomer (B) is represented by the following formula (2): (In the formula, R 2 represents a hydrogen atom or a methyl group, and z represents an integer of 1 to 10.
8. A medical adhesive comprising the medical polymer composition according to any one of claims 1 to 7.
9. The medical adhesive according to claim 8, which is used for at least one application selected from the group consisting of coating the surface of biological tissue, joining biological tissues together, and joining biological tissue to medical equipment.
10. The medical adhesive according to claim 8, which is used for at least one application selected from the group consisting of prevention of inflammation, bleeding and stenosis inside the digestive tract, prevention of colonic anastomotic failure, prevention of pancreatic fistula, prevention of bleeding after formation of a dialysis shunt, prevention of enlargement of varicose veins of the lower extremities, and prevention of vascular stenosis.
Citation Information
Patent Citations
Bio-intelligent electroresponsive cell microcarrier and preparation method and application thereof
CN111423531A
Copolymer containing NVP structure and application thereof in lubricating coating for interventional catheter
CN115819671A
Composition, cured film, laminate, vessel, underwater structure, medical device, and microchannel chip
JP2021123712A
Compressor and Chiller including the same
KR1020210093663A
Cited By
Polymer composition and medical adhesive containing same
WO2025205896A1
